Portage Biotech (PRTG)
(Delayed Data from NSDQ)
$5.85 USD
+0.46 (8.53%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $5.77 -0.08 (-1.37%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Portage Biotech Inc falls in the month of March.
All items in Millions except Per Share data.
3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 5 | 11 | 23 | 3 | 3 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 3 | 3 | 1 | 2 | 1 |
Total Current Assets | 8 | 14 | 25 | 5 | 4 |
Net Property & Equipment | 0 | 82 | 117 | 117 | 117 |
Investments & Advances | 0 | 3 | 9 | 9 | 9 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 43 | 43 | 43 |
Deposits & Other Assets | 0 | 1 | 0 | 0 | 0 |
Total Assets | 8 | 99 | 195 | 175 | 173 |
Liabilities & Shareholders Equity | 3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 0 | 2 | 1 | 2 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 1 | 1 |
Total Current Liabilities | 3 | 2 | 1 | 3 | 3 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 11 | 28 | 24 | 22 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 2 | 11 | 0 | 0 | 3 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 4 | 24 | 29 | 27 | 28 |
Shareholders Equity | 3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 220 | 219 | 158 | 131 | 118 |
Capital Surplus | 0 | 0 | 0 | 0 | 0 |
Retained Earnings | -239 | -160 | -55 | -38 | -22 |
Other Equity | 23 | 16 | 62 | 55 | 50 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 3 | 75 | 165 | 148 | 146 |
Total Liabilities & Shareholder's Equity | 8 | 99 | 195 | 175 | 173 |
Total Common Equity | 3 | 75 | 165 | 148 | 146 |
Shares Outstanding | 0.80 | 0.80 | 0.60 | 0.60 | NA |
Book Value Per Share | 4.16 | 94.25 | 275.72 | 246.00 | 0.00 |
Fiscal Year End for Portage Biotech Inc falls in the month of March.
All items in Millions except Per Share data.
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 3 | 5 | 5 | 3 | 8 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 2 | 3 | 2 | 2 | 3 |
Total Current Assets | 5 | 8 | 8 | 6 | 11 |
Net Property & Equipment | 0 | 0 | 35 | 82 | 82 |
Investments & Advances | 0 | 0 | 6 | 3 | 5 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 1 | 1 | 1 |
Total Assets | 5 | 8 | 49 | 92 | 98 |
Liabilities & Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 0 | 3 | 3 | 3 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 3 | 3 | 3 | 3 | 3 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 10 | 10 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 15 | 13 | 12 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 3 | 4 | 18 | 25 | 26 |
Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 220 | 220 | 219 | 219 | 219 |
Capital Surplus | 0 | 0 | 0 | 0 | 0 |
Retained Earnings | -241 | -239 | -210 | -171 | -166 |
Other Equity | 23 | 23 | 22 | 18 | 19 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 2 | 3 | 31 | 67 | 73 |
Total Liabilities & Shareholder's Equity | 5 | 8 | 49 | 92 | 98 |
Total Common Equity | 2 | 3 | 31 | 67 | 73 |
Shares Outstanding | 0.80 | 0.80 | 0.80 | 0.80 | 0.80 |
Book Value Per Share | 2.26 | 4.16 | 39.16 | 83.75 | 90.81 |